125I放射性粒子植入联合放化疗治疗中晚期非小细胞肺癌的疗效观察

doi:10.3760/cma.j.issn.1673-422X.2017.10.005

摘要/Abstract

摘要： 目的回顾性分析125I放射性粒子植入联合放化疗治疗中晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法82例周围型NSCLC患者按照不同的治疗方法分为实验组（n=32）和对照组（n=50），实验组行125I放射性粒子植入联合同步放化疗治疗，对照组行同步放化疗治疗。两组患者均采用螺旋断层放疗，化疗方案采用PC方案（紫杉醇+顺铂）或TP方案（多西他赛+顺铂）。观察有效率（RR）、无进展生存期（PFS）、总生存期（OS）及不良反应发生情况。结果实验组与对照组有效率分别为87.5%和76.0%，差异无统计学意义（χ2=0.992，P=0.319）；中位PFS分别为16个月和11个月，差异有统计学意义（χ2=5.216，P=0.022）；中位OS分别为26个月和19个月，差异无统计学意义（χ2=1.085，P=0.298）。实验组和对照组不良反应如放射性肺炎（18.75%∶24.00%，χ2=0.314，P=0.575）、放射性食管炎（25.00%∶30.00%，χ2=0.242，P=0.623）、消化道反应（21.88%∶26.00%，χ2=0.180，P=0.671）、骨髓抑制（12.50%∶16.00%，χ2=0.014，P=0.907）和血气胸（6.25%∶0，P=0.149）发生率的差异均无统计学意义。结论125I放射性粒子植入联合同步放化疗是中晚期NSCLC安全、有效的治疗方法，值得进一步研究和推广。

关键词: 肺肿瘤, 放射疗法, 药物疗法, 125I粒子近距离放射治疗

Abstract: ObjectiveTo review the efficacy and safety of combination of iodine125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage nonsmall cell lung cancer (NSCLC). MethodsEightytwo cases of peripheral NSCLC patients were divided into the experimental group (n=32) and the control group (n=50) by different treatment methods. The patients in experimental group were treated by iodine125 brachytherapy combined with concurrent chemoradiotherapy, and the patients in control group were treated by concurrent chemoradiotherapy. The two groups were treated with helical tomotherapy, and the chemotherapy regimen was PC regimen (paclitaxel + cisplatin) or TP regimen (taxotere + cisplatin). The response rate (RR), progression free survival (PFS), overall survival (OS) and adverse reactions were observed. ResultsThe RR of experimental group and control group was 87.5% and 76.0%, and the difference was not statistically significant (χ2=0.992, P=0.319). The median PFS was 16 months and 11 months, and the difference was statistically significant (χ2=5.216, P=0.022). The median OS was 26 months and 19 months, and the difference was not statistically significant (χ2=1.085, P=0.298). There were no statistically significant differences of the occurrence rates of adverse reactions in the experimental group and the control group such as radioactive pneumonia (18.75% vs. 24.00%, χ2=0.314, P=0.575), radiation esophagitis (25.00% vs. 30.00%, χ2=0.242, P=0.623), digestive tract reaction (21.88% vs. 26.00%, χ2=0.180, P=0.671), bone marrow suppression (12.50% vs. 16.00%, χ2=0.014, P=0.907) and hemopneumothorax (6.25% vs. 0, P=0.149). ConclusionThe combination of iodine125 brachytherapy with concurrent chemoradiotherapy is a safe and effective treatment for middle and advanced stage NSCLC, which is worthy of further research and promotion.

Key words: Lung neoplasms, Radiotherapy, Drug therapy, Iodine125 brachytherapy

孙颖,王宁,郭占文,阎英. 125I放射性粒子植入联合放化疗治疗中晚期非小细胞肺癌的疗效观察[J]. 国际肿瘤学杂志, 2017, 44(10): 740-744.

Sun Ying, Wang Ning, Guo Zhanwen, Yan Ying. Curative effect of iodine125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(10): 740-744.

参考文献

［1］ Wagner TD, Yang GY. The role of chemotherapy and radiation in the treatment of locally advanced nonsmall cell lung cancer (NSCLC)［J］. Curr Drug Targets, 2010, 11(1): 6773. ［2］ Fleischman EH, Kagan AR, Streeter OE, et al. Iodine125 interstitial brachytherapy in the treatment of carcinoma of the lung［J］. J Surg Oncol, 1992, 49(1): 2528. ［3］ MartínezMonge R, Pagola M, Vivas I, et al. CTguided permanent brachytherapy for patients with medically inoperable earlystage nonsmall cell lung cancer (NSCLC)［J］. Lung Cancer, 2008, 61(2): 209213. DOI: 10.1016/j.lungcan.2007.12.016. ［4］ Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase Ⅲ randomized trial for highrisk operable nonsmallcell lung cancer［J］. J Clin Oncol, 2014, 32(23): 24562462. DOI: 10.1200/JCO.2013.53.4115. ［5］ Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)［J］. Int J Radiat Oncol Biol Phys, 1995, 31(5): 13411346. DOI: 10.1016/03603016(95)00060C. ［6］孙文泽, 宋丽萍, 张莹冰, 等. 93例Ⅲ期非小细胞肺癌同步放化疗加巩固化疗与序贯放化疗的对比研究［J］. 南方医科大学学报, 2012, 32(3): 362367. DOI: CNKI: 441627/R.20120307.1635.018. ［7］ Kim M, Lee J, Ha B, et al. Factors predicting radiation pneumonitis in locally advanced nonsmall cell lung cancer［J］. Radiat Oncol J, 2011, 29(3): 181190. DOI: 10.3857/roj.2011.29.3.181. ［8］ Chen HH, Jia RF, Yu L, et al. Bystander effects induced by continuous lowdoserate 125I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro［J］. Int J Radiat Oncol Biol Phys, 2008, 72(5): 15601566. DOI: 10.1016/j.ijrobp.2008.07.038. ［9］ Guckenberger M, Kavanagh A, Partridge M. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage Ⅲ nonsmall cell lung cancer［J］. Strahlenther Onkol, 2012, 188(10): 894900.DOI: 10.1007/s0006601201619. ［10］ Wang ZM, Lu J, Liu T, et al. CTguided interstitial brachytherapy of inoperable nonsmall cell lung cancer［J］. Lung Cancer, 2011, 74(2): 253257. DOI: 10.1016/j.lungcan.2011.03.006. ［11］ Chen H, Bao Y, Yu L, et al. Comparison of cellular damage response to lowdoserate 125I seed irradiation and highdoserate gamma irradiation in human lung cancer cells［J］. Brachytherapy, 2012, 11(2): 149156. DOI: 10.1016/j.brachy.2011.05.002. ［12］ Suchorska B, Ruge M, Treuer H, et al. Stereotactic brachytherapy of lowgrade cerebral glioma after tumor resection［J］. Neuro Oncol, 2011, 13(10): 11331142. DOI: 10.1093/neuonc/nor100. ［13］ Huckle A, AIQaisieh B, Bownes P. Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy［J］. Radiother Oncol, 2012, 103(2): 261265. DOI: 10.1016/j.radonc.2011.09.022. ［14］蒲德利, 张福君, 廖江荣, 等. 放射性125I粒子联合化疗治疗晚期非小细胞肺癌的临床研究［J］. 当代医学, 2010, 16(23): 450452. DOI: 10.3969/j.issn.10094393.2010.23.021. ［15］张福君, 李传行, 吴沛宏, 等. 125I粒子组织间植入治疗局部晚期肺癌的对比研究［J］. 中华医学杂志, 2007, 87(46): 32723275. ［16］黄德波, 肖宝荣. 局部晚期非小细胞肺癌的同步放化疗［J］. 国际肿瘤学杂志, 2013, 40(10): 755758. DOI: 10.3767/cma.j.issn.1673422X.2013.10.011.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[9]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[10]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[11]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[14]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[15]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.